Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Moderna Inc (NASDAQ: MRNA) closed at $45.65 in the last session, up 2.72% from day before closing price of $44.44. In other words, the price has increased by $2.72 from its previous closing price. On the day, 7.27 million shares were traded. MRNA stock price reached its highest trading level at $47.4126 during the session, while it also had its lowest trading level at $44.1001.
Ratios:
We take a closer look at MRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Berenberg on November 19, 2024, initiated with a Hold rating and assigned the stock a target price of $42.
On November 18, 2024, HSBC Securities Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $58.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Underperform rating and target price of $40.Wolfe Research initiated its Underperform rating on November 15, 2024, with a $40 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 09 ’24 when Klinger Shannon Thyme bought 529 shares for $44.68 per share.
Klinger Shannon Thyme sold 112 shares of MRNA for $4,849 on Dec 03 ’24. The Chief Legal Officer now owns 19,837 shares after completing the transaction at $43.30 per share. On Dec 03 ’24, another insider, Hoge Stephen, who serves as the President of the company, sold 314 shares for $43.30 each. As a result, the insider received 13,595 and left with 1,443,904 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 17566941184 and an Enterprise Value of 12054933504. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.58 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 2.373 whereas that against EBITDA is -5.104.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $35.80. The 50-Day Moving Average of the stock is -9.26%, while the 200-Day Moving Average is calculated to be -51.33%.
Shares Statistics:
According to the various share statistics, MRNA traded on average about 7.26M shares per day over the past 3-months and 8101320 shares per day over the past 10 days. A total of 385.00M shares are outstanding, with a floating share count of 343.14M. Insiders hold about 10.83% of the company’s shares, while institutions hold 67.52% stake in the company. Shares short for MRNA as of 1731628800 were 39863421 with a Short Ratio of 5.49, compared to 1728950400 on 33260603. Therefore, it implies a Short% of Shares Outstanding of 39863421 and a Short% of Float of 13.63.
